PPARγ is also an important regulator of lipid metabolism, and clinical studies demonstrated that PPARγ agonists can significantly reduce hepatic steatosis and improve NAFLD symptoms (Skat‐Rørdam et al., 2019). This evidence concerns the gene PPARG and fatty liver disease.